Acacia Pharma Group plc Notice Of Full Year 2020 Results
18 March 2021 - 6:00PM
UK Regulatory
TIDMACPH
Acacia Pharma to Report its Results for the Full Year 2020 and Provide a
Business Update on 29 March 2021
Cambridge, UK and Indianapolis, US -- 18 March 2021, 08:00 CET: Acacia
Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a
commercial stage biopharmaceutical company focused on developing and
commercializing novel products to improve the care of patients
undergoing serious medical treatments such as surgery, invasive
procedures, or chemotherapy, announces that it will report its results
for the full year 2020 and provide an update on progress with the
commercialization of BARHEMSYS(R) and BYFAVO(TM) on Monday, 29 March
2021 at 07.00 CEST.
A presentation by Acacia Pharma's senior management team will be webcast
live the same day at 14.30 CEST (08.30 EST).
The webcast can be accessed from
https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3qcK9ixDRtqA3w76T_pT3oWeketBMFgj_3sOHC9kYscZlwN0FVM6OkG2EJKQa5UEC8=
www.acaciapharma.com and a recording will be available after the event.
The results report and presentation will be available at
https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3rKUtALNSzb1b8tkt2JOIWjYzTk9UbQ_vk1BgVTIOh5i8F6p62k63plJpw7KtHA6Cg=
www.acaciapharma.com in the Investors section from 07.00 CEST the same
day.
###
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@citigatedewerogerson.com
acaciapharma@citigatedewerogerson.com
----------------------------------------------- ---------------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ---------------------------------------------
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
marketed in the US for the management of postoperative nausea & vomiting
(PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centered in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
https://www.globenewswire.com/Tracker?data=SLPS7CKhbOXlINx9yToCnmn8dRRT2mXBhB5z_knAv3oOXDBZuPOxEpOotqqjnjh94_z7tDSDH-MiRog-T_xG14emxaJGSQqaePYDi6hfliE=
www.acaciapharma.com
(END) Dow Jones Newswires
March 18, 2021 03:00 ET (07:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Acacia Pharma Group Plc (London Stock Exchange): 0 recent articles
More Acacia Pharma Group Plc News Articles